Stay updated with breaking news from Adjuvant Setting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts explore neoadjuvant HER2+ breast cancer care, delve into treatment goals, predictors, and personalized approaches, and uncover insights on chemotherapy, trastuzumab, and post-op considerations.
Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival?
Chronic immune-related adverse events often persist years after adjuvant anti–PD-1 immunotherapy for high-risk melanoma and may require prolonged monitoring and management, researchers say.
A new analysis found that relapse-free survival is a poor surrogate endpoint for overall survival in adjuvant immunotherapy trials in a variety of cancer types.